Host cell surface molecules mediating AnelloVector attachment and entry

Host cell surface molecules mediating AnelloVector attachment and entry represent the primary cellular interface for the AnelloVector gene therapy platform, developed by Ring Therapeutics. These molecules, which likely include a combination of proteinaceous receptors and glycan attachment factors (such as sialic acids), are recognized by the viral capsid protein (ORF1) of engineered anelloviruses. Anelloviruses are a diverse family of commensal, non-pathogenic viruses that are ubiquitous in the human population, offering a unique advantage for gene delivery due to their low immunogenicity and ability to be redosed. While the specific identities of these host molecules are currently being characterized, they are known to dictate the tissue-specific tropism of different anellovirus genera, such as Betatorquevirus. The interaction between the vector and these surface molecules triggers receptor-mediated endocytosis, allowing the delivery of therapeutic genetic material into the host cell nucleus where it remains as an episome. This targeting mechanism is central to the development of programmable medicines for a wide range of indications, including genetic disorders, oncology, and ophthalmology.

Other names

Anellovirus receptorsAnelloVector entry receptorsTorque teno virus receptorsTTV attachment factorsAnelloviridae entry factors

AnelloVectors utilize their capsid proteins (primarily ORF1) to bind specific host cell surface molecules, triggering receptor-mediated endocytosis and subsequent delivery of therapeutic DNA to the nucleus as an episome.